Phase 2
18 Years
80 Years
18 Years
80 Years
Not Enrolling
Both
Myelodysplastic Syndrome
Both
Myelodysplastic Syndrome
Trial Information
Inclusion Criteria
- Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not
therapy related.
- Patient must be able to adhere to the study visit schedule and other protocol
requirements.
- Patient must understand and voluntarily sign an informed consent document.
- Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
test.
- Women must not be pregnant or lactating.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
CC-1088-MDS-801-001
NCT ID:
NCT00045786
Start Date:
October 2001
Completion Date:
November 2005
Related Keywords:
- Myelodysplastic Syndrome
- myelodysplastic syndrome
- Myelodysplastic Syndromes
- Preleukemia
Name | Location |
|---|---|
| Rush-Presbyterian-St Luke's Medical Center | Chicago, Illinois 60612-3515 |
